WebJan 1, 2006 · REACH was an international, prospective, observational registry that followed patients with or at high risk of atherothrombosis from 44 countries. Baseline data were collected, and patients were followed for up to 4 years. Principal Findings: WebFeb 1, 2024 · Importance: REACH is the first phase 3 trial to provide information on hepatocellular cancer (HCC) in the second-line (postsorafenib) setting categorized by Child-Pugh score, a scoring system used to measure the severity of chronic liver disease. This exploratory analysis demonstrates the relationship between a potential ramucirumab …
Efficacy and Safety of Losmapimod in Treating Patients With ...
WebNov 3, 2016 · Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. Blood. 2024 May 14;135 (20):1739-1749. doi: … WebMay 14, 2024 · Various treatment strategies have been tested for steroid-refractory aGVHD 8,20-25 ; however, the REACH1 study is the first prospective clinical trial demonstrating a … greek invasion of albania
Ruxolitinib for the treatment of steroid-refractory acute …
WebMar 3, 2011 · Briefly, 288 patients were enrolled in this open-label, phase 2 trial from December 1999 through April 2008. Four patients were excluded as they did not have a diagnosis of CLL leaving 284 previously treated patients with CLL (supplemental Figure 1). WebThe REACH trial was not designed or powered to detect a significant difference in PFS by age category. However, exploratory analysis defined by age suggests no observed benefit with the addition of RITUXAN to FC chemotherapy in previously treated CLL patients 65 years of age or older. SELECT IMPORTANT SAFETY INFORMATION WebJul 21, 2024 · REACH1 was a phase 2 single-arm trial carried out at several centers across the United States that involved 71 patients with steroid-refractory acute graft versus host disease (aGVHD) and treated these patients with ruxolitinib. Patients were given a dose of ruxolitinib of 5 mg twice a day to start, and if after 3 days they tolerated it, the ... flowella tx